Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
01/09/2026 06:01
BRIEF-BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi Sept 1 (Reuters) - BioArctic AB (publ) BIOAb.ST:
CANADA'S DRUG AGENCY ISSUES FINAL POSITIVE RECOMMENDATION SUPPORTING PUBLIC REIMBURSEMENT OF LEQEMBI®
NEXT STEPS INCLUDE NEGOTIATIONS AND REIMBURSEMENT DECISIONS BY PUBLIC DRUG PLANS IN CANADA
Source text: ID:nWkr51rq5c
Further company coverage: [BIOAb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln